The site is undergoing maintenance. Ordering can continue through fax and phone.
Sunday, August 16, 2026, 1:30 - 4:30 pm (CEST).
If you encounter problems while ordering. Please contact us at BDBCustomerService@bd.com
See More
The site is undergoing maintenance. Ordering can continue through fax and phone.
Sunday, August 16, 2026, 1:30 - 4:30 pm (CEST).
If you encounter problems while ordering. Please contact us at BDBCustomerService@bd.com
See MoreThe site is undergoing maintenance. Ordering can continue through fax and phone.
Sunday, August 16, 2026, 1:30 - 4:30 pm (CEST)
.If you encounter problems while ordering. Please contact us at BDBCustomerService@bd.com
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Expression of CD138 on mouse bone- marrow B lymphocytes. BALB/c bone- marrow leukocytes were stained with purified 281-2 mAb (Right panel), followed by biotinylated goat anti-rat Ig (Cat. no. 554014, both panels), then blocked with normal rat serum (both panels) and stained with Streptavidin-PE (Cat. no. 554061, both panels) and FITCconjugated RA3-6B2 mAb (anti-mouse CD45R/B220, Cat. no. 553087/553088, both panels). Flow cytometry was performed on a BD FACScan™ Flow Cytometry System.
Expression of CD138 on mouse bone- marrow B lymphocytes. BALB/c bone- marrow leukocytes were stained with purified 281-2 mAb (Right panel), followed by biotinylated goat anti-rat Ig (Cat. no. 554014, both panels), then blocked with normal rat serum (both panels) and stained with Streptavidin-PE (Cat. no. 554061, both panels) and FITCconjugated RA3-6B2 mAb (anti-mouse CD45R/B220, Cat. no. 553087/553088, both panels). Flow cytometry was performed on a BD FACScan™ Flow Cytometry System.
Expression of CD138 on mouse bone- marrow B lymphocytes. BALB/c bone- marrow leukocytes were stained with purified 281-2 mAb (Right panel), followed by biotinylated goat anti-rat Ig (Cat. no. 554014, both panels), then blocked with normal rat serum (both panels) and stained with Streptavidin-PE (Cat. no. 554061, both panels) and FITCconjugated RA3-6B2 mAb (anti-mouse CD45R/B220, Cat. no. 553087/553088, both panels). Flow cytometry was performed on a BD FACScan™ Flow Cytometry System.
Expression of CD138 on mouse bone- marrow B lymphocytes. BALB/c bone- marrow leukocytes were stained with purified 281-2 mAb (Right panel), followed by biotinylated goat anti-rat Ig (Cat. no. 554014, both panels), then blocked with normal rat serum (both panels) and stained with Streptavidin-PE (Cat. no. 554061, both panels) and FITCconjugated RA3-6B2 mAb (anti-mouse CD45R/B220, Cat. no. 553087/553088, both panels). Flow cytometry was performed on a BD FACScan™ Flow Cytometry System.
Expression of CD138 on mouse bone- marrow B lymphocytes. BALB/c bone- marrow leukocytes were stained with purified 281-2 mAb (Right panel), followed by biotinylated goat anti-rat Ig (Cat. no. 554014, both panels), then blocked with normal rat serum (both panels) and stained with Streptavidin-PE (Cat. no. 554061, both panels) and FITCconjugated RA3-6B2 mAb (anti-mouse CD45R/B220, Cat. no. 553087/553088, both panels). Flow cytometry was performed on a BD FACScan™ Flow Cytometry System.
Expression of CD138 on mouse bone- marrow B lymphocytes. BALB/c bone- marrow leukocytes were stained with purified 281-2 mAb (Right panel), followed by biotinylated goat anti-rat Ig (Cat. no. 554014, both panels), then blocked with normal rat serum (both panels) and stained with Streptavidin-PE (Cat. no. 554061, both panels) and FITCconjugated RA3-6B2 mAb (anti-mouse CD45R/B220, Cat. no. 553087/553088, both panels). Flow cytometry was performed on a BD FACScan™ Flow Cytometry System.
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
CD138 is expressed at low density on cells in the normal bone marrow; therefore, it may be desirable to amplify staining by using a biotinylated second-step antibody followed by a "bright" third-step reagent, such as Streptavidin-PE (Cat. no. 554061). Other reported applications include western blot analysis using a cationic blotting membrane and a specific method, ELISA, and immunohistochemical staining of acetone-fixed frozen and paraffin-embedded sections.
The 281-2 monoclonal antibody specifically binds to the core protein of CD138 (Syndecan-1), a cell-surface, integral membrane heparan sulfate- and chondroitin sulfate-containing proteoglycan that binds to interstitial extracellular matrix molecules. Syndecan-1 is predominantly expressed on epithelial cells, where its expression correlates with normal epithelial organization. It is also expressed on B lymphocytes at specific stages during their differentiation: precursor B cells in the bone marrow, and antibody-secreting cells including plasma cells (but not mature peripheral B cells). It is thus implicated in mediating B cell-matrix interactions. CD138 expression is also regulated during embryonic development, and the molecule shows a tissue- specific structural polymorphism resulting from different post-translational modifications. The 281-2 antibody may be used to detect the differently glycosylated forms, because it reacts with the core protein. Furthermore, the mAb detects the Syndecan-1 ectodomain which is cleaved from cell surfaces by a metalloproteinase.
This antibody is routinely tested by flow cytometric analysis. Other application were tested at BD Biosciences Pharmingen during development only or reported in the litererature.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.